Description
The 17C9 monoclonal antibody specifically recognizes Complement receptor of the immunoglobulin superfamily (CRIg) which is encoded by the Vsig4 (V-set and immunoglobulin domain containing 4) gene. CRIg is a ~45 kDa single-pass type I transmembrane glycoprotein that contains a variable (V-type) immunoglobulin domain in its extracellular region which is required for binding complement components and promoting phagocytosis. CRIg is expressed on Kupffer cells and tissue resident macrophages, including a subset of resident peritoneal macrophages. CRIg binds complement fragments C3b and iC3b and plays important roles in innate and adaptive immunity. This complement receptor is involved in regulation of the complement cascade and serves as a phagocytic receptor in the clearance of pathogens, immune complexes, and apoptotic cells. CRIg-positive macrophages can reportedly function in the negative regulation of T-cell proliferation and IL-2 production.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV786 under optimal conditions that minimize unconjugated dye and antibody.
1. This antibody was developed for use in flow cytometry.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Researchers should determine the optimal concentration of this reagent for their individual applications.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
9. BD Horizon Brilliant Violet 786 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
10. Cy is a trademark of GE Healthcare.
